Nope, Anthony...can't let you get away with that one. BMY is keeping their options open, and was actually quite positive about it's future.....READ BELOW
*******
YOU SAID" NCI<---NON PROFIT " feel good group"
Bristol Meyers<-------FOR-PROFIT " CAN it make money?....NO! ...OK Can IT!!!"
*******
That ain't it and you know it.
FROM YESTERDAYS, BMY Press Release:
Under their revised agreement, EntreMed, based in
suburban Washington, D.C., is now responsible for
all upcoming work on the molecule. Bristol-Myers
Squibb has the option to "reassume" development
and marketing once proof that the protein meets its
criteria for clinical trials becomes clear.
Research conducted at Children's Hospital in
Boston had showed promise, reducing tumors in
mice by cutting blood supplies to cancerous areas.
But angiostatin hasn't been tested on humans.
"At this time, Angiostatin protein in its present form
does not meet our criteria for molecules that
advance to clinical trials," Robert A. Kramer, vice
president of oncology drug discovery for
Bristol-Myers, said in a press release.
"We have chosen to direct our resources to other
programs in our broad oncology pipeline. We
continue, however, to view antiangiogenesis as an important and viable
target in the spectrum of oncology research," he added. |
